BACE1 and early-onset autosomal dominant Alzheimer disease: BACE1 provides a promising therapeutic target for Alzheimer's disease (AD) and numerous BACE1 inhibitors have been designed, of which several have gone into clinical trials (Klaver et al, 2010; Vassar et al, 2009; Woo et al, 2011).